- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01986543
Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection (RIFAVIRENZ)
We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the absence of data about R induction at this dose. Due to an important inter-patient variability of the CYP2B6 polymorphism, the EFV pharmacokinetic (Pk) will be compared in same patients with and without TB treatment.
The main objective is to compare the Pk parameters of EFV in HIV-TB co-infected patients, with and without TB treatment, using R at 10 and 20mg/Kg/day and EFV at 600 and 800mg/day.
Study Overview
Detailed Description
Justification: In vitro and animal studies have shown that increasing the dose of rifampicin (R) improves the R sterilising effect. If a similar effect can be demonstrated in the clinical setting, this could allow shortening treatment duration from 6 to 4 months, with good tolerance. Several phase 2 trials in HIV-negative patients are ongoing. We propose a first interaction study between efavirenz (EFV) and R20mg/Kg taking into consideration the absence of data about R induction at this dose. Due to an important inter-patient variability of the CYP2B6 polymorphism, the EFV pharmacokinetic (Pk) will be compared in same patients with and without TB treatment.
Principal objective: To compare the Pk parameters of EFV in HIV-TB co-infected patients, with and without TB treatment, using R at 10 and 20mg/Kg/day and EFV at 600 and 800mg/day.
Secondary objectives: To describe the Pk parameters of R and isoniazid (H); the TB treatment réponse (Mycobacterium tuberculosis culture conversion after 8 weeks(w) and cure after 24w) ; the virological response; the occurrence of severe adverse events, especially hepatic and neurological events; the treatment adherence; the genes involved in the EFV metabolism of EFV, R and H, and its relation with the Pk parameters.
Primary endpoint: AUC0-24, Cmax, Cmin, Tmax of EFV after 4w of TB treatment + ARV, and 4w after interruption of TB treatment.
Study design : phase 2 randomized, open label 3 arms therapeutic trial:
- Arm 1 : 8 weeks R20mg/Kg + H + pyrazinamide(Z)+ ethambutol(E) and EFV600mg/J + tenofovir-lamivudine
- Arm 2: 8 weeks R20mg/Kg + H+Z+E and EFV800mg/J + tenofovir-lamivudine
- Standard arm : 8 weeks R10mg/Kg + H+Z+E and EFV600mg/J + tenofovir-lamivudine
The ARV treatment will be initiated 4 weeks after starting TB treatment. After 8 weeks, all patients will receive 16 weeks of H+R with R at 10mg/Kg/day and EFV at 600mg/day. Treatment will be observed at home by a domiciliary treatment monitor (DTM). Patients will be followed during 28 weeks after starting TB treatment: weekly visit during first 8 weeks and then every 4 weeks.
Pk sampling for EFV, R and H will be at w2 (Pk1), w8 (Pk2) and w28 (Pk3). Liver function test and full blood count will be measured after 2, 4 and 8 weeks; sputum culture for TB at baseline and w8; HIV-1 RNA at baseline, w4, w12 and w24 and CD4 count at baseline and w24.
Eligibility criteria: > 18 years old; previously untreated pulmonary TB; Xpert confirming Mtb susceptible to R; body weight >45Kg; CD4 between 50 and 250cells/mm3; Karnofsky score >80%; ALAT/biluribin <5xULN; no grade 4 clinical/biological sign; no pregnancy + barrier contraception; agree to participate and sign a consent form.
Randomisation block, 1:1:1. Sample size: 28 patients to show that the reduction of AUC of EFV with R20mg/Kg vs no R is not greater to 30%, with 20% expected reduction. Same number per study arm and 20% increase for patients' withdrawals or lost to follow-up resulting in a total of 105 patients.
Site: Mbarara (Uganda)
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Mbarara PO box 1956, Mbarara, Uganda
- Mbarara Research Base
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged of 18 years or more
- Diagnosis of new pulmonary tuberculosis confirmed by a XpertMTB/RIF test
- Positive HIV antibody test, naïve of ART with CD4 cell count between 50 and 250cells/mm3
- For women of childbearing age, to have a negative urine test for pregnancy on the day of enrolment and to accept to take a barrier contraception during the period of the trial
- Participants well enough to receive ambulatory treatment
- Weight > 45Kg
- Home address readily accessible
- Participants providing informed consent to participate in the trial
Exclusion Criteria:
- Rifampicin drug resistance based on the XpertMTB/RIF result confirmed by the GenotypeMTBDRplus assay
- Concomitant opportunistic infection requiring additional infectious medication
- Karnofsky score <80%
- ALAT or bilirubin > 5.0 x ULN (hepatitis grade 3 or 4)
- Haemoglobin < 7.5g/dL (grade 3 or 4)
- Grade 4 clinical sign or biological result according to the ANRS for grading the intensity of adverse events
- Patient not able to give his informed consent or is unlikely or unable to cooperate with sampling procedures
- Patient suffering of psychiatric illness, which may prevent follow-up according to the protocol
- Patients receiving or requiring medications that may interfere with study drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
8 weeks R20mg/Kg + HZE and efavirenz 600mg
|
|
Experimental: Arm 2
8 weeks R20mg/Kg + HZE and efavirenz 800mg
|
|
Active Comparator: Standard arm
8 weeks R10mg/Kg + HZE and efavirenz 600mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efavirenz through concentration before drug intake (Cmin); maximal concentration (Cmax); time to achieve the Cmax (Tmax) and area under the curve of concentrations vs time at steady state during a 24-hour dosing interval (AUC0-24)
Time Frame: Week 8
|
Week 8
|
Efavirenz Cmin; Cmax; Tmax; AUC0-24
Time Frame: Week 28
|
Week 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetic parameters of R and H (Cmin, Cmax and AUC0-24)
Time Frame: Week 2
|
Week 2
|
Pharmacokinetic parameters of R and H (Cmin, Cmax and AUC0-24)
Time Frame: Week 8
|
Week 8
|
Mycobacterium tuberculosis culture of sputum
Time Frame: week 8
|
week 8
|
Plasma HIV-1 RNA
Time Frame: week 28
|
week 28
|
Grade 3 and 4 adverse events
Time Frame: 0-28 weeks
|
0-28 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: BONNET Maryline, MD, Epicentre MSF
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- HIV Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Coinfection
Other Study ID Numbers
- ANRS 12292 RIFAVIRENZ
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on drug administration
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRICompleted
-
Guangdong Provincial People's HospitalCompletedChemotherapy | Non Small Cell Lung Cancer | Immunotherapy | Tumour, ResidualChina
-
Escola Superior de Enfermagem de CoimbraHospital de Braga; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Hospital...UnknownSafety Issues | Medical Device
-
Eurofarma Laboratorios S.A.Not yet recruiting
-
University Hospital TuebingenHumboldt-Universität zu Berlin; University of Greifswald; Herzzentrum Bad KrotzingenUnknownArterial Occlusive DiseasesGermany
-
Centre hospitalier de l'Université de Montréal...Withdrawn
-
Royan InstituteCompleted
-
PATHTulane University; Ministry of Health, Zambia; Minister of Community Development...CompletedMalaria | Malaria, FalciparumZambia
-
PATHMinistry of Health, Zambia; AKROS Global HealthCompleted